trending Market Intelligence /marketintelligence/en/news-insights/trending/hatxnlv4tpf6zy7u7fyr9g2 content esgSubNav
In This List

Cancer Genetics gets Nasdaq noncompliance notice

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Cancer Genetics gets Nasdaq noncompliance notice

Rutherford, N.J.-based Cancer Genetics Inc. said it failed to comply with Nasdaq's $1 minimum bid price per share for its common shares.

The biotechnology company, which develops molecular and biomarker-based tests and services, has 180 calendar days, or until Feb. 4, 2019, to regain compliance.